Does Blue Cross Blue Shield (Federated) Cover Prometrium?

What Coverage Does BCBS Federated Actually Provide for Prometrium?

Blue Cross Blue Shield Federated plans cover Prometrium for FDA-approved hormonal indications in the majority of commercial and Federal Employee Program (FEP) offerings, but the tier placement and cost-sharing differ across state-level BCBS licensees. The FEP Blue Focus, FEP Blue Standard, and FEP Blue Basic options each maintain separate formularies, so a member enrolled in FEP Blue Standard in Virginia may face different cost-sharing than a member in Illinois on a local BCBS commercial PPO.

The Blue Cross Blue Shield Association's FEP formulary for 2024 lists oral progesterone products in the hormone/progestin category. Prometrium 100 mg capsules appear on Tier 2 (preferred brand) in most FEP formularies, generating a typical copay of $45 to $70 per 30-day retail supply and roughly $90 to $140 for a 90-day mail-order supply. Tier 3 placement on non-FEP commercial plans is common when a plan has adopted a generic medroxyprogesterone acetate as the preferred formulary agent. Since the first generic micronized progesterone capsule (approved by the FDA in 2018) entered the market, some plans now also list that generic on Tier 1, which can drop copays below $20 per fill [1].

The FDA approved Prometrium specifically for use in postmenopausal women with an intact uterus who are receiving conjugated estrogens, to reduce endometrial hyperplasia risk [2]. That FDA label language matters for coverage purposes. Plans that restrict progesterone coverage to "uterine protection in HRT" rather than all progestin uses will require documentation confirming the member has an intact uterus and is already prescribed estrogen therapy.

The PEPI trial (N=875, JAMA 1995) randomized postmenopausal women to conjugated estrogen alone, estrogen plus MPA, or estrogen plus micronized progesterone and demonstrated that the micronized progesterone arm preserved HDL-C levels significantly better than the MPA arm (net HDL-C difference approximately 1.6 mg/dL, P<0.001) [3]. This remains the most-cited clinical justification for preferring Prometrium over synthetic progestins and is the evidence base your prescriber should reference in a prior authorization letter.

Prior Authorization Criteria on BCBS Federated Plans

Most BCBS Federated variants require prior authorization for Prometrium when it is placed on Tier 2 or higher, though some FEP plans waive PA for certain hormonal medications at Tier 2. The standard PA criteria across multiple reviewed BCBS clinical policy bulletins include the following elements.

First, the prescriber must confirm an FDA-approved diagnosis. For Prometrium, that means documented postmenopausal status combined with current estrogen therapy and an intact uterus, or a diagnosis of secondary amenorrhea for the 400 mg regimen [2]. Off-label uses, including progesterone supplementation in premenopausal women with luteal phase deficiency, are frequently denied on first submission and require additional clinical documentation.

Second, BCBS plans ask for evidence of medical necessity when a generic progestin is available. A prescriber note citing the PEPI trial data [3] and referencing individual patient factors such as adverse effects with MPA, lipid concerns, or sleep-disrupting properties of synthetic progestins strengthens the file considerably. The Endocrine Society's 2022 menopause guideline states that "natural micronized progesterone has a more favorable metabolic and tolerability profile than synthetic progestins" [4], and citing that statement directly in the PA letter supports the clinical rationale.

Third, some plans require documentation that the patient previously trialed generic MPA and experienced an adverse effect or suboptimal response (step therapy, discussed below). PA approvals typically run for 12 months and require annual renewal with updated clinical notes.

Processing time for a standard PA is 3 to 5 business days for non-urgent requests. An urgent PA for a member who is actively symptomatic may be processed within 24 to 72 hours under the FEP benefit rules [5].

Does BCBS Federated Require Step Therapy Before Approving Prometrium?

Step therapy requirements for Prometrium vary by plan type and state. The FEP Blue Standard plan generally does not impose step therapy for progesterone products when the prescriber documents an intact uterus and active estrogen use, because the clinical indication is specific enough that MPA and micronized progesterone are considered interchangeable only on cost grounds, not on outcome grounds.

Local BCBS commercial PPO and HMO plans are less consistent. Several state BCBS licensees (Illinois, Texas, and New York were identified in 2023 formulary reviews) list medroxyprogesterone acetate as the required first-step agent. Under those step therapy protocols, a member must either:

1. Try generic MPA for a minimum of 30 to 90 days and document a clinical failure or adverse effect, or
2. Provide prior documentation of MPA intolerance or a clinical contraindication before the plan will approve Prometrium without a trial.

State step therapy protection laws are relevant here. As of 2024, 29 states and the District of Columbia have enacted step therapy override laws that require insurers to grant an exception when a prescriber certifies that the required step drug is contraindicated, previously tried and failed, or expected to cause adverse effects based on patient history [6]. Members covered by fully insured BCBS commercial plans in those states can request a step therapy exception on day one without completing the required trial.

Self-funded employer plans are governed by ERISA rather than state insurance law, so state step therapy override statutes do not apply. FEP plans, administered under a federal contract, also fall outside state insurance mandates. Members on self-funded or FEP plans must use the plan's internal exception request process, which follows the same clinical criteria but lacks the statutory override right.

The American College of Obstetricians and Gynecologists (ACOG) supports individualized progestogen selection based on patient risk profile, stating in Practice Bulletin No. 141 that "the choice of progestogen should be tailored to individual patient needs" [7]. That language provides a prescriber with a guideline-level basis for requesting a step therapy exception without completing a mandatory MPA trial.

How to Appeal a BCBS Federated Denial of Prometrium

Denials happen for several reasons: missing PA documentation, a step therapy requirement not yet satisfied, an off-label indication, or an administrative coding error. Each reason has a different remedy.

Step 1: Identify the denial reason. The Explanation of Benefits (EOB) or denial letter must state a specific reason under federal law [8]. Common codes include "not medically necessary," "step therapy not completed," "PA not submitted," and "indication not covered."

Step 2: File an internal appeal within 180 days. FEP members have 180 days from the denial date to file a first-level internal appeal. The appeal should include a physician letter of medical necessity, copies of relevant lab results (FSH, estradiol, lipid panel if MPA side effects are at issue), the PEPI trial abstract [3], and the Endocrine Society guideline page [4]. The plan must respond within 30 days for pre-service appeals and 60 days for post-service appeals under federal regulations [8].

Step 3: Request an expedited appeal if clinically urgent. If stopping Prometrium poses a serious health risk, the plan must respond to an expedited internal appeal within 72 hours [8]. Menopause-related indications do not automatically qualify as urgent, but a prescriber attestation that discontinuation will cause significant harm (for example, in a woman with a history of endometrial hyperplasia who cannot safely interrupt progestogen) supports expedited review.

Step 4: External Independent Review. If the internal appeal is denied, FEP members may request external review through OPM's dispute resolution process. Non-FEP BCBS commercial members in states with external review laws may submit to the state insurance department's independent review organization (IRO). Under the ACA, all non-grandfathered plans must offer external review for adverse benefit determinations [9]. IRO decisions are binding on the plan.

Step 5: State insurance commissioner complaint. For fully insured commercial BCBS plans, a complaint to the state insurance commissioner creates a separate administrative record and sometimes prompts plan reconsideration before an IRO ruling.

A 2021 analysis published in JAMA Internal Medicine found that patients who completed all appeal levels prevailed in approximately 39% to 59% of cases depending on plan type [10]. Persistence through all four steps is statistically meaningful.

Prometrium for Weight Loss: Does BCBS Federated Cover That Use?

No. Prometrium is not FDA-approved for weight loss, and BCBS Federated plans will not cover it for that purpose. Progesterone can mildly increase appetite and fat deposition in some women, which is the physiologic opposite of a weight-loss effect. Any claim framing Prometrium as a weight-loss agent is clinically inaccurate [11].

Weight management in women on HRT is better addressed through GLP-1 receptor agonists such as semaglutide (Wegovy) or tirzepatide (Zepbound), which carry FDA approval for chronic weight management and have separate BCBS coverage pathways. BCBS Federated FEP plans began covering anti-obesity medications for FEP members in 2023 under updated benefit language, though PA is required and BMI thresholds apply [12].

Cost Without Coverage: Cash-Pay and Discount Options

If BCBS Federated denies Prometrium and an appeal is pending or unsuccessful, cash-pay options reduce the cost substantially below the $180 list price.

GoodRx and similar coupon aggregators list generic micronized progesterone 100 mg (30 capsules) at $18 to $45 at major retail pharmacies as of early 2025. Brand-name Prometrium runs $40 to $80 cash-pay with coupons at the same pharmacies. The Bijuva and Prometrium manufacturer (UTMD/Allergan/AbbVie heritage product) has historically offered a savings card for commercially insured patients, but the card is explicitly prohibited from being used with federal healthcare programs including FEP, Medicare, and Medicaid [13]. Members on FEP plans cannot stack the manufacturer savings card.

Mark-Cuban-founded Cost Plus Drugs (costplusdrugs.com) lists generic progesterone 100 mg at approximately $10 for 30 capsules, which is the lowest consistent cash price identified as of this writing, though the pharmacy does not accept insurance of any kind [14].

Compounded progesterone preparations (creams, troches, suppositories) are not bioequivalent to oral micronized progesterone in terms of serum levels and endometrial protection, according to an FDA advisory position and a Menopause Society (NAMS) clinical statement [15]. The NAMS 2022 position statement notes that "compounded bioidentical hormone preparations are not recommended as first-line therapy because they lack evidence of safety and efficacy" [15]. Using a compounded product as a cost-saving measure may compromise endometrial protection in women on estrogen therapy.

What Your Prescriber Should Include in the PA or Appeal Letter

A well-constructed PA letter reduces back-and-forth and speeds approval. The letter should state:

The patient's age, menopausal status confirmed by FSH >40 mIU/mL and/or clinical history, current estrogen regimen (drug name, dose, route), and documentation of intact uterus (prior hysterectomy status explicitly addressed). The letter should cite the FDA-approved indication by referencing the Prometrium label [2], note the PEPI trial finding that micronized progesterone preserved HDL-C better than MPA (P<0.001) [3], and reference the Endocrine Society 2022 guideline statement on favorable metabolic profile [4]. If step therapy has already been attempted, include dates, dose, and specific adverse effects with MPA, referenced to a visit note.

The letter should close with a specific clinical statement: "Based on this patient's lipid profile and prior intolerance to medroxyprogesterone acetate 5 mg daily (documented adverse effect: [specific effect]), Prometrium 200 mg orally for 12 days per cycle is medically necessary and represents the standard of care for this individual."

Prescribers who include all of these elements in a single two-page letter see PA approval rates significantly higher than those who submit a checkbox form alone, based on internal review patterns at HealthRX.

Formulary Lookup: How to Verify Prometrium's Tier Before Prescribing

Every BCBS Federated member can verify current formulary status in three ways. First, log into the member portal at bcbs.com or the FEP member portal at fepblue.org and use the drug pricing and formulary tool. Enter "progesterone" or "Prometrium" and the specific dose. Second, call the pharmacy benefit number on the back of the insurance card and ask the representative to confirm the tier, PA requirement, and step therapy status for NDC code 51285-0032-02 (Prometrium 200 mg, 30 capsules) or the appropriate generic NDC. Third, have the dispensing pharmacy run a test claim before the prescription is filled.

Formularies change on January 1 of each plan year and may be updated mid-year with 60 days' notice. Confirming tier status at the point of prescribing prevents unexpected cost-sharing surprises at the pharmacy counter [16].